CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million

Stock News

03/31

CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.

According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1134093030"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134093030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134093030?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 01:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134093030","market":"nz","top_or_hot":-1,"title":"CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million","media":"Stock News","content":"<p>CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.</p>\n<p>According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-31 01:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.</p>\n<p>According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1134093030","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134093030","pubTimestamp":1774892659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02592":"拨康视云-B"},"translate_title":"CLOUDBREAK-B报告年度亏损收窄6766万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02592":1},"content_text":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.\nAccording to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}